| Listed site | cro | cro |
|---|
| Summary | Amador Bioscience provides bioanalysis and biomarker services, including LCMS, immunoassays, flow cytometry, and immunogenicity testing, alongside clinical pharmacology modeling and regulatory affairs support. Its labs are GLP compliant, and its teams work across the US, China, and Europe. | Certara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making. |
|---|
| Services | - Bioanalysis
- Ligand-Binding Bioanalysis (Large Molecule)
- LC-MS Bioanalysis (Small Molecule)
- Immunogenicity Assays (ADA / NAb)
- Flow Cytometry Services
- Biomarker Assays
- Biostatistics & Statistical Programming
- Translational Research
- Regulatory Affairs
- Clinical Trial Services
- Clinical Operations
- Phase IV / Post-Marketing
| - Biostatistics & Statistical Programming
- Data Management & eClinical
- Regulatory Affairs
- Medical Writing
- Computational & In-Silico Drug Discovery
- Translational Research
- Target Identification & Validation
- High-Throughput Screening
- Medicinal Chemistry
- In Vitro Pharmacology
- In Vitro ADME / DMPK
- Safety Pharmacology
- Genetic Toxicology
- Discovery Research
- In Vivo Efficacy Models
- In Vivo PK / PD Studies
- GLP Toxicology
- Preclinical In Vitro Studies
- Preclinical In Vivo Studies
- Bioanalysis
- LC-MS Bioanalysis (Small Molecule)
- Ligand-Binding Bioanalysis (Large Molecule)
- Phase I Clinical Trials
- Biomarker Assays
- Phase II Clinical Trials
- Phase III Clinical Trials
- Clinical Operations
- Phase IV / Post-Marketing
- US FDA Regulatory Strategy
- US FDA Regulatory Strategy
- EU EMA Regulatory Strategy
- EU EMA Regulatory Strategy
- Japan PMDA Regulatory Strategy
- Japan PMDA Regulatory Strategy
- China NMPA Regulatory Strategy
- China NMPA Regulatory Strategy
- Clinical Trial Services
|
|---|
| Modalities | - Antibody-Drug Conjugate (ADC)
- Oligonucleotide
- Peptide
- Small Molecule
- Cell Therapy
- Gene Therapy
- mRNA
- Vaccine
- Biologics (Other)
| - Small Molecule
- Small Molecule
- Biologics (Monoclonal Antibodies)
- Biologics (Monoclonal Antibodies)
- Biologics (Other)
- Biologics (Other)
- Peptide
- Peptide
- Oligonucleotide
- Oligonucleotide
- mRNA
- mRNA
- Antibody-Drug Conjugate (ADC)
- Antibody-Drug Conjugate (ADC)
- Gene Therapy
- Gene Therapy
- Cell Therapy
- Cell Therapy
- Vaccine
- Vaccine
|
|---|
| Indications | Data not yet provided. | - Oncology
- Rare Disease
- Immunology
- Immunology
- Neurology
- Neurology
- Psychiatry
- Metabolic
- Metabolic
- Cardiovascular
- Cardiovascular
- Infectious Disease
- Infectious Disease
- Respiratory
- Respiratory
- Dermatology
- Dermatology
- Ophthalmology
- Ophthalmology
- Gastroenterology
- Gastroenterology
- Nephrology
- Nephrology
- Women's Health
- Women's Health
|
|---|
| Locations | - California, California, United States
- Maryland, Maryland, United States
- Michigan, Michigan, United States
- Belgium, Belgium
- Hangzhou, Hangzhou, China
- Shanghai, Shanghai, China
- Beijing, Beijing, China
| - Global network
- Global presence, 30 countries
- Global presence, Multiple, 30 countries, Global
- Global presence, Multiple, 30+ countries
- Global presence, Multiple, 30 countries, International
- Headquarters, Radnor, Pennsylvania, United States
- Global presence, 30 countries
- Global presence, 30+ countries
|
|---|
| Certifications | Data not yet provided. | Data not yet provided. |
|---|
| Reviews | Review summary appears after site-level review signal gate opens. | Review summary appears after site-level review signal gate opens. |
|---|